Clinical tests of a vaccine from a malaria have passed successfully

Results of two large clinical tests in Africa have shown efficiency of a new vaccine from a malaria - the case rate at inoculated was reduced more than half.
Vaccine RTS, S developed by large pharmaceutical company GlaxoSmithKline at Initiative support «the Vaccine against a malaria» contains the unique antigen specific. Prepared by vaccine introduction the immune system attacks the originator at this stage, not supposing its hit in a liver for the further reproduction.
809 children have taken part in the first clinical buy Revatio  test at the age of 5-17 months from Kenya and Tanzania. 402 from them have received a vaccine injection, then they remained under observation within eight months. For this term with a malaria 32 children from inoculated and 66 - from control group were ill, and at inoculated disease developed more longly. Thus, efficiency of a preparation in this research has made 53 %.
In the second research which has included 340 children from Tanzania, efficiency of a vaccine has appeared still above and has made 65 %. It was besides, found out, that activity RTS, S did not decrease at simultaneous appointment with inoculations from a tetanus, a diphtheria and a whooping cough that supposes creation of the combined preparation.
Researchers and independent experts are online ultram 50 mg  quite satisfied by efficiency of a vaccine, but converge that duration of its action should become object of the further researches. The further working out and vaccine industrial production are expedient, if it operates not less than 3-4 years.
According to representative GlaxoSmithKline, the following stage of clinical tests is planned the next year. It will include 16 000 children from 11 various points of Africa. If the success proves to be true, the vaccine can already become widely accessible in 2012. Further including in on line phentermine a vaccine of antigens of other stages of development of a plasmodium for the further rising of its efficiency is possible.
Annually with a malaria is ill approximately 515 million persons, of one to three millions from them dies. The most part of victims of a malaria - children living in Africa to the south of Sahara.